#United States #California #Pomerantz Law Firm #Aardvark Therapeutics #ARD-101

Pomerantz Law Firm's Class Action Against Aardvark Therapeutics

On September 17, 2026, Pomerantz LLP announced the initiation of a class action lawsuit targeting Aardvark Therapeutics, Inc. and several of its key officers and directors. This legal action, which has been filed in the United States District Court for the Southern District of California, primarily involves allegations that misleading information was presented to investors during Aardvark's initial public offering (IPO).

Background of Aardvark Therapeutics

Aardvark is identified as a clinical-stage biopharmaceutical company emphasizing the development of innovative therapies designed to suppress hunger and address metabolic disorders such as Prader-Willi Syndrome (PWS). PWS is characterized by a persistent, insatiable hunger, leading to various health challenges. Aardvark's current focus is encapsulated in their product candidate ARD-101, acknowledged for its gut-restricted action on specific taste receptors associated with hunger regulation.

The company entered the public market on February 13, 2025, offering 5,888,000 shares at a price of $16.00 per share, raising approximately $87.6 million. This initial funding was meant to propel forward their ambitious clinical programs, notably a Phase 3 clinical trial known as the Hunger Elimination or Reduction Objective (HERO) trial to evaluate the efficacy of ARD-101 in managing hyperphagia in PWS patients.

Allegations of Misleading Statements

The complaint encompasses allegations that Aardvark's Offering Documents were inadequately prepared, containing false statements or failing to disclose significant facts about the company's products and their prospects. Of particular concern to the plaintiffs is the assertion that ARD-101 posed greater safety risks than represented, with claims suggesting that deceiving statements were made about its clinical, regulatory, and commercial outlook.

During the class period, from February 13, 2025, until May 14, 2026, the company reportedly made materially misleading claims regarding its business viability and the development success of its products, leading to significant losses for investors who acted upon this information. The lawsuit seeks to hold the company accountable under the Securities Act of 1933 and the Securities Exchange Act of 1934, providing a legal avenue for those affected.

Importance of Investor Participation

Investors who acquired Aardvark securities through the IPO or during the aforementioned class period are encouraged to participate in the lawsuit. Pomerantz LLP urges eligible claimants to act swiftly, as they have until October 13, 2026, to apply for the position of Lead Plaintiff in the class action. Details about the class action can be accessed via Pomerantz Law Firm's website.

Developments Affecting Aardvark's Stock

A pivotal moment for Aardvark occurred on February 27, 2026, when the company announced a voluntary pause in the HERO trial due to concerns over cardiac observations from routine safety monitoring. Following this revelation, Aardvark’s stock plummeted by over 56%, highlighting the market's reaction to the emerging safety concerns.

Furthermore, as of May 14, 2026, Aardvark faced a full clinical hold imposed by the FDA on its investigational new drug application (IND) for ARD-101, as the suspension of all related clinical trials took effect. The drop in stock price continued, demonstrating the adverse impact of these developments on investor confidence and stock performance.

About Pomerantz Law Firm

Pomerantz LLP, known for its expertise in securities class actions, has been a staunch advocate for investor rights for over 85 years. The firm has a proven track record of recovering damages for victims of corporate misconduct and securities fraud. Interested investors should connect with Pomerantz using the contact details provided in this announcement for further guidance or to seek assistance related to this case.

In summary, the class action lawsuit against Aardvark Therapeutics emphasizes the importance of accountability in corporate disclosures and the protection of investor interests, especially within the biopharmaceutical sector where clinical outcomes can dramatically affect company valuations and investor liquidity.